New Disposable VUSE GO 5000 and VUSE GO 6000 Launched

InnovationVUSE by 2FIRSTS.ai
Nov.23.2023
New Disposable VUSE GO 5000 and VUSE GO 6000 Launched
VUSE recently launched "VUSE GO 5000" and "VUSE GO 6000" disposable products in the Middle East market.

On November 23, 2FIRSTS, a popular vaping brand, discovered that VUSE has launched new disposable products called "VUSE GO 5000" and "VUSE GO 6000" in the Middle East market. These products come in high nicotine content variants, with the "VUSE GO 5000" offering 5000 puffs and the "VUSE GO 6000" offering 6000 puffs.

New Disposable VUSE GO 5000 and VUSE GO 6000 Launched
The product "VUSE GO 6000" sold on the VUSE official website | Image source: VUSE

 

These two products each come in 5 different flavors, namely mango ice, grape ice, blueberry ice, mint ice, and blue raspberry.

New Disposable VUSE GO 5000 and VUSE GO 6000 Launched
The product "VUSE GO 5000" is sold on the official VUSE website. Image source: VUSE.

 

The official retail price of VUSE GO 5000 is 80 dirhams, equivalent to approximately 155 Chinese yuan.

 

Previously, 2FIRSTS conducted market research in Russia and found that VUSE had launched a product with a range of 5000 puffs in that market, with a retail price of 1300 Russian rubles, approximately 95 Chinese yuan, which was 60 Chinese yuan lower than the official VUSE website in the Middle East.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

JT launches limited-edition Ploom AURA front panels; two go on sale, three offered via prize draw
JT launches limited-edition Ploom AURA front panels; two go on sale, three offered via prize draw
Japan Tobacco (JT) has rolled out an Ichiro Yamaguchi collaboration under its Ploom AURA “SENSATIONAL” campaign, using a combined marketing push—limited sales, a prize draw, video content distribution and in-store displays—to release five front panels and two branded accessories. Two panels will go on sale from Jan. 27, while the remaining panels and accessories will be distributed through a draw running from Jan. 19 to Feb. 28.
Jan.19 by 2FIRSTS.ai
U.S. Fifth Circuit judges question FDA’s claim it has no de facto ban on flavored refillable e-cigarettes
U.S. Fifth Circuit judges question FDA’s claim it has no de facto ban on flavored refillable e-cigarettes
Law360 reports that a Fifth Circuit panel expressed skepticism about the FDA’s claim that it has no de facto ban on flavored refillable e-cigarette products, noting that only six applications had been approved out of hundreds of thousands and that near-100% denials look like a ban.
Jan.07 by 2FIRSTS.ai
IQOS UK unveils 2026 pop-up events plan, first stops set for London and three other cities
IQOS UK unveils 2026 pop-up events plan, first stops set for London and three other cities
IQOS’ UK website shows the company will roll out time-limited pop-up experience spaces across Britain in 2026 for adult consumers. The first confirmed locations are London, the West Midlands area near Birmingham, Manchester and Romford, offering product demonstrations, pop-up-only promotions and nicotine pouch sampling. Entry will be restricted to those aged 18 and over, with “Challenge 25” ID checks in place.
Feb.03 by 2FIRSTS.ai
Kentucky to issue provisional state licenses to tobacco, nicotine and vapor retailers who applied before Jan. 1, 2026
Kentucky to issue provisional state licenses to tobacco, nicotine and vapor retailers who applied before Jan. 1, 2026
Kentucky will issue provisional state licenses to tobacco, nicotine and vapor product retailers that applied for a license with the Department of Alcoholic Beverage Control (ABC) before Jan. 1, 2026.
Dec.31 by 2FIRSTS.ai
Türkiye’s trade minister: valued at USD 40 million in illicit e-cigarette products seized over five years
Türkiye’s trade minister: valued at USD 40 million in illicit e-cigarette products seized over five years
Türkiye’s Trade Minister Ömer Bolat said that over the past five years, authorities carried out 4,589 operations seizing 28,683,985 e-cigarette devices and parts and 1,070,586 grams/ml of e-liquid, valued at TL 1,762,796,000 (about USD 40,544,308).
Jan.20 by 2FIRSTS.ai
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24